On November 11, 2026, Turkey's Social Security Institution (Sosyal Güvenlik Kurumu, SGK), through the General Directorate of General Health Insurance (Genel Sağlık Sigortası Genel Müdürlüğü), published Announcement 2026/44, Bedeli Ödenecek İlaçlar Listesinde Yapılan Düzenlemeler Hakkında Duyuru 2026/44, on amendments to the list of pharmaceuticals whose cost SGK reimburses. The notice is the Article 12 list update (12. Madde) and points to two files dated for publication on November 13, 2026: the PDF "12. MADDE DUYURUSU 13.11.2026" and the workbook "13.11.2026 12.MADDE-YAYIM.xlsx", both linked from the SGK announcement page.
Pharmaceutical marketing authorisation holders with reimbursed products on the Turkish market, importers of pharmaceuticals placed on the Turkish reimbursement list (Bedeli Ödenecek İlaçlar Listesi), and Turkish-market pharmaceutical companies whose products face reimbursement status changes in Announcement 2026/44 must review the updated Article 12 reimbursable pharmaceuticals list for additions, removals and reimbursement condition changes, and adjust reimbursement claims, pricing compliance and supply, by November 13, 2026, or products removed from the list lose SGK reimbursement, meaning no real market access in Turkey where SUT listing is a block-level requirement for reimbursement. The line-by-line changes are not on the webpage: they sit in the PDF and the workbook, which a market-access team matches to its own portfolio.
What does Announcement 2026/44 change on the reimbursable list?
Announcement 2026/44 tells the market that the Article 12 reimbursable pharmaceuticals list is amended with the November 13, 2026 publication. The Sağlık Uygulama Tebliği (SUT) is the Health Implementation Communiqué through which SGK publishes the reimbursable pharmaceuticals list.
The page, dated November 11, 2026, carries two attachments and no product table of its own. The PDF is the Article 12 announcement for November 13, 2026. The workbook is the Article 12 publication file for the same day. Additions, removals and reimbursement-condition changes are in those files.
| Attachment | Date on the file | What it is for |
|---|---|---|
| 12. MADDE DUYURUSU 13.11.2026.pdf | November 13, 2026 | Article 12 announcement of the list update |
| 13.11.2026 12.MADDE-YAYIM.xlsx | November 13, 2026 | Publication workbook of the Article 12 list changes |
The PDF is also a direct SGK download: 12. MADDE DUYURUSU 13.11.2026.pdf. The workbook sits on the same announcement page. Announcement 2026/44 is a separate notice from Announcement 2026/43: a different number, with publication on November 13, 2026.
Who must act on the Article 12 list by November 13, 2026?
The companies exposed are marketing authorisation holders of reimbursed products, importers who place pharmaceuticals on the Bedeli Ödenecek İlaçlar Listesi, and Turkish-market companies whose reimbursement status this announcement changes.
TİTCK grants the marketing authorisation (ruhsat). The Ministry of Health coordinates the Pricing Evaluation Commission, which sets the price. SGK decides reimbursement through the SUT list, with TEDK (Tıbbi ve Ekonomik Değerlendirme Komisyonu) doing the clinical and pharmacoeconomic evaluation. A valid ruhsat does not keep a product reimbursed once SGK removes it from Article 12. Obsidian tracks 9 regulatory texts, in force, amended or in preparation, for the Life Sciences & MedTech industry in Turkey as of November 2026.
Ordinary SUT application windows fall at the end of March and the end of July. Announcement 2026/44 is a list publication dated November 13, 2026, so the check is against these two files, not against the next scheduled round.
What must marketing authorisation holders check before November 13, 2026?
Each exposed company matches its Turkish portfolio to the November 13, 2026 workbook and the Article 12 PDF, then changes claims, price compliance and supply only where those files show a change for its own products.
- Download the November 13, 2026 PDF and the 12.MADDE-YAYIM workbook from the Announcement 2026/44 page.
- Match each reimbursed product, by name and marketing authorisation, to additions, removals and condition changes in the workbook.
- Where a product is removed, stop treating it as SGK-reimbursed from November 13, 2026 and reset claims that assume listing.
- Where a reimbursement condition changes in the file, update the claim logic and the internal price file to that condition.
- Where a product is added, confirm the ruhsat, the approved price and the new listing before the first reimbursed supply.
A per-jurisdiction monitoring watch on SGK announcements is how a list file of this kind is picked up when the General Directorate posts it.
What happens if a product is no longer on the list?
Products removed from the list lose SGK reimbursement. SUT listing is a block-level requirement for reimbursement in Turkey: without it there is no real reimbursed market access, even when the marketing authorisation stays in force. The announcement states no separate administrative fine for missing the November 13, 2026 publication. The consequence the listing rule already carries is the loss of reimbursement. This notice does not reset the euro coefficient used for list prices, and it does not replace a TİTCK safety or authorisation duty.
Open both November 13, 2026 files, mark every portfolio line that is added, removed or given a new reimbursement condition, and align claims and supply to that mark from November 13, 2026. Obsidian keeps each numbered SGK notice on the same Turkey watch as the SUT list.
